10. A trihydrochloride dihydrate salt of the compound of formula (I) according to claim 8 having a XRPD pattern comprising one or more peaks selected from 5.42 ± 0.2 degrees 2Θ, 5.91 ± 0.2 degrees 2Θ, 8.86 ± 0.2 degrees 2Θ, 10.80 ± 0.2 degrees 2Θ, 11.79 ± 0.2 degrees 2Θ, 14.06 ± 0.2 degrees 2Θ, 14.72 ± 0.2 degrees 2Θ, 17.02 ± 0.2 degrees 2Θ, 17.52 ± 0.2 degrees 2Θ and 18.51 ± 0.2 degrees 2Θ.

11. A pharmaceutical composition comprising a compound or salt according to any of claims 1-10 and a pharmaceutically acceptable excipient.

12. The pharmaceutical composition of claim 11, wherein said composition is in the form of a tablet or capsule.

13. A method of treating an ALK- or FAK-mediated condition or disorder in a subject, comprsing the step of administering to the subject a therapeutically effective amount of a compound or a salt of any of claims 1-10.

14. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), neuroblastoma, glioblastoma, prostate cancer, squamous cell carcinoma (SCC), and breast cancer.

15. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, neuroblastoma, glioblastoma, androgen-independent prostate cancers, breast cancers, and head and neck squamous cell carcinomas (HNSCCs).

16. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, neuroblastoma, androgen-independent prostate cancers, breast cancers, and HNSCCs.

17. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, neuroblastoma, and glioblastoma.

18. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, and neuroblastoma.

19. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL and EML4-ALK-positive NSCLC.

20. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from androgen-independent prostate cancers, breast cancers, and HNSCCs.

21. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is an ALK-mediated condition or disorder.

22. The method of claim 13, wherein the ALK- or FAK-mediated condition or disorder is a FAK-mediated condition or disorder.

10. A trihydrochloride dihydrate salt of the compound of formula (1) according to claim 8 having a XRPD pattern comprising one or more peaks selected from 5.42 ± 0.2 degrees 2Θ, 5.91 ± 0.2 degrees 2Θ, 8.86 ± 0.2 degrees 2Θ, 10.80 ± 0.2 degrees 2Θ, 11.79 ± 0.2 degrees 2Θ, 14.06 ± 02 degrees 2Θ, 14.72 ± 0.2 degrees 2Θ, 17.02 ± 0.2 degrees 2Θ, 17.52 ± 0.2 degrees 2Θ and 18.51 ± 0.2 degrees 2Θ.

11. A pharmaceutical composition comprising a compound or salt according to any of claims 1-10 and a pharmaceutically acceptable excipient.

12. The pharmaceutical composition of claim 11, wherein said composition is in the form of a tablet or capsule.

13. Use of a compound or a salt of any of claims 1-10 for the manufacture of a medicament for treating an ALK- or FAK-mediated condition or disorder.

14. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), neuroblastoma, glioblastoma, prostate cancer, squamous cell carcinoma (SCC), and breast cancer.

15. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, neuroblastoma, glioblastoma, androgen-independent prostate cancers, breast cancers, and head and neck squamous cell carcinomas (HNSCCs).

16. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, neuroblastoma, androgen-independent prostate cancers, breast cancers, and HNSCCs.

17. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, neuroblastoma, and glioblastoma.

18. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL, EML4-ALK-positive NSCLC, and neuroblastoma.

19. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from ALK-positive ALCL and EML4-ALK-positive NSCLC.

20. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is selected from androgen-independent prostate cancers, breast cancers, and HNSCCs.

21. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is an ALK-mediated condition or disorder.

22. The use of claim 13, wherein the ALK- or FAK-mediated condition or disorder is a FAK-mediated condition or disorder.